Major Depressive Disorder Clinical Trial
Official title:
A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Major Depression Disorder (MDD)
Verified date | February 2013 |
Source | Brainsway |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation), a new experimental procedure using the H-Coil, in subjects with Major Depressive Disorder that have been previously unsuccessfully treated with antidepressant medications.
Status | Completed |
Enrollment | 233 |
Est. completion date | June 2012 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 68 Years |
Eligibility |
Inclusion Criteria: - Outpatients. - Men and women 22-68 years of age. - Primary DSM-IV diagnosis of Major Depression, single or recurrent episode. - Current depressive episode is less than 5 years duration. - The patient did not respond to at least one but not more than four antidepressant treatments in the current episode. - Patients who have not completed antidepressant trials due to intolerance to therapy of 2 or more anti-depressant medications in the current episode. - Satisfactory safety screening questionnaire for transcranial magnetic stimulation. - Patients not suffering from hypo or hyper-thyroidism based on pre-study TSH level or medically stabilized. - Patients able to tolerate psychotropic medication washout and no psychotropics during the treatment, other than benzodiazepine at equivalent daily dose of up to 3 mg lorazepam. Exclusion Criteria: - A history of schizophrenia, any psychotic disorder, PTSD, bipolar disorder, OCD, eating disorders (e.g., anorexia nervosa, bulimia) or substance abuse - A history of panic disorder, social anxiety disorder or personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic) as assessed by the investigator to be primary, causing a higher degree of distress or impairment than MDD. - A history of any significant medical disease (i.e., cardiovascular, gastrointestinal, etc.) - A history of seizures, at risk for seizure (e.g., history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes or familial or personal history of epilepsy) or have been diagnosed with a seizure disorder. - Undergone rTMS treatment, Vagus Nerve Stimulation, or Deep Brain Stimulation. - Received ECT within the last 3 months or failed to respond to ECT treatment. - Individuals with a significant neurological disorder or insult including: - Any condition likely to be associated with increased intracranial pressure - Space occupying brain lesion - Any history of seizure EXCEPT those therapeutically induced by ECT - History of cerebrovascular accident - Transient ischemic attack within two years - Cerebral aneurysm - Dementia - Parkinson's disease - Huntington's chorea - Multiple sclerosis - Individuals with hearing loss. - Any intracranial implant such as aneurysm clips, shunts, stimulators, cochlear implants, or electrodes, or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. - A cardiac pacemaker, implanted medication pump, intracardiac line, or acute, unstable cardiac disease. - Use of fluoxetine within 6 weeks of the randomization visit. - Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the randomization visit. - Present suicidal risk as assessed by the investigator. - Implanted neurostimulators. - History of abnormal MRI. - If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial. - Clinically significant laboratory abnormality, in the opinion of the Investigator based on CBC and biochemistry. - Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse. - Women: if pregnant, planning on becoming pregnant, or currently nursing. |
Country | Name | City | State |
---|---|---|---|
Canada | Center for Addiction and Mental Health (CAMH) | Toronto | Ontario |
France | EPS Ville-Evrard | Neuilly Sur Marne | |
Germany | Universitätsklinikum Bonn, Klinik und Poliklinik für Psychiatrie und Psychotherapie | Bonn | |
Germany | Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität | Munich | |
Israel | Beer Yaacov Mental Health Center | Beer Yaacov | |
Israel | Shalvata Mental Health Center | Hod Hasharon | |
Israel | Hadasah Ein-Karem Medical Center | Jerusalem | |
Israel | Kfar Shaul Mental Health Center | Jerusalem | |
United States | Senior Adults Specialty Research | Austin | Texas |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | McLean Hospital - TMS Services | Belmont | Massachusetts |
United States | Medical Uni. Of South Carolina (MUSC) | Charleston | South Carolina |
United States | UT Southwestern Medical Center at Dallas | Dallas | Texas |
United States | Duke Medical Center Department of Psychiatry & Behavioral Sciences | Durham | North Carolina |
United States | Advanced Mental Health Care Inc. - Juno Beach | Juno Beach | Florida |
United States | University of California (UCLA) | Los Angeles | California |
United States | Greater Nashua Mental Health Center | Nashua | New Hampshire |
United States | Columbia University / New York State Psychiatric Institute | New York | New York |
United States | Neuropharmacology Services | New York | New York |
United States | Advanced Mental Health Care Inc. - Royal Palm Beach | Royal Palm Beach | Florida |
United States | UC Davis Center for Mind & Brain | Sacramento And Davis | California |
United States | Smart Brain and Health | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
Brainsway |
United States, Canada, France, Germany, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HDRS-21 | 5 weeks | ||
Secondary | Response rate | 5 weeks | ||
Secondary | Remission rates | 5 weeks | ||
Secondary | Quality of Life | 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |